|
Report summarizes cannabis? role in moderating disease |
|
|
|
|
Written by Jaime Galindo
|
|
Thursday, 16 November 2006 |
Review of 120+ recent studies confirms that in the US, politics trumps science
Recently published clinical and preclinical research on the therapeutic use of cannabis indicates that cannabinoids may curb the progression of various life-threatening diseases — in particular, auto-immune disorders such as Multiple Sclerosis, rheumatoid arthritis and inflammatory bowel disease, as well as neurological disorders such as Alzheimer’s disease and Amyotrophic Lateral Sclerosis (a.k.a. Lou Gehrig’s disease) – according to a comprehensive new report published today by the NORML Foundation.
It’s clear that the US government’s stance against the therapeutic use of cannabis and cannabinoids is based on politics, not science.
The NORML Foundation report summarizes over 120 recently published trials assessing the therapeutic utility of cannabinoids for the treatment of fifteen specific disease indications:
• Alzheimer’s Disease
• Amyotrophic Lateral Sclerosis
• Diabetes Mellitus
• Dystonia
• Fibromyalgia
• Gastrointestinal Disorders
• Gliomas
• Hepatitis C
• Hypertension
• Incontinence
• Osteoporosis
• Pruritis
• Rheumatoid Arthritis
• Sleep Apnea
• Tourette’s Syndrome
“Despite continued political debates regarding the recreational use of
cannabis, clinical investigations of the therapeutic use of cannabinoids are
now more prevalent than at any time in history,” states the report’s author, NORML Foundation Senior Policy Analyst Paul Armentano. “In some of these cases, modern science is now affirming longtime anecdotal reports of
medicinal cannabis users. In other cases, this research is highlighting entirely new potential clinical utilities for cannabinoids.”
Whereas initial clinical investigations into the therapeutic use of cannabis focused primarily on whether cannabinoids might provide symptomatic relief, investigators today are exploring the potential role of cannabinoids to inhibit the progression of several life-threatening diseases – including cancer, Armentano says.
“Arguably, this latter trend represents far broader and more significant applications for cannabinoid therapeutics than researchers could have imagined some thirty or even twenty years ago,” he concludes.
“Unfortunately, because of the US government’s strong public policy stance against any use of marijuana, the bulk of this modern research is taking place outside the United States and continues to go unrecognized in North America. Nevertheless, the emerging body of clinical and preclinical work published over the past six years makes it clear that the US government’s stance against the therapeutic use of cannabis and cannabinoids is based on politics, not science.”
Full text of the report, “Emerging Clinical Applications For Cannabis & Cannabinoids: A Review of the Recent Scientific Literature, 2000 – 2006,” is available online in HTML and PDF formats at: http://www.norml.org/index.cfm?Group_ID=7002.
For more information, please contact Paul Armentano, NORML Foundation Senior Policy Analyst, at (202) 483-5500 or via e-mail at:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
|
Jaime Galindo |
| About the author: |
| Managing editor for Oaksterdam News |
| Read More >> | |
|
Last Updated ( Monday, 20 November 2006 )
|
The Men's Wearhouse George Zimmer
